← FDA DRUG APPROVALS

FDA ANDA · ANDA077244

CARBOPLATIN

Sponsor: HIKMA

APPLICATION
ANDA077244
TYPE
ANDA
ORIGINAL APPROVAL
2004-10-15
LATEST ACTION
2012-03-13
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CARBOPLATINPrescription
CARBOPLATIN 150MG/15ML (10MG/ML) · INJECTABLE · INTRAVENOUS
CARBOPLATINPrescription
CARBOPLATIN 450MG/45ML (10MG/ML) · INJECTABLE · INTRAVENOUS
CARBOPLATINPrescription
CARBOPLATIN 50MG/5ML (10MG/ML) · INJECTABLE · INTRAVENOUS
CARBOPLATINPrescription
CARBOPLATIN 600MG/60ML (10MG/ML) · INJECTABLE · INTRAVENOUS

Approval history

2012-03-13Labeling · Supplement 10AP
2011-09-07Labeling · Supplement 8AP
2006-01-20Labeling · Supplement 3AP
2006-01-20Manufacturing (CMC) · Supplement 2AP
2005-07-11Labeling · Supplement 1AP
2004-10-15OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →